SAB Biotherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
SAB Biotherapeutics (Nasdaq: SABS) announced that co-founder and CEO Eddie J. Sullivan, PhD, will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The presentation will be available for on-demand viewing starting January 10 at 7:00 a.m. ET. SAB focuses on developing novel immunotherapies using fully-human polyclonal antibodies, targeting various diseases, including infectious diseases and cancer. Their DiversitAb™ platform aims to meet serious unmet medical needs.
- None.
- None.
SIOUX FALLS, S.D., Jan. 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that Eddie J. Sullivan, PhD, co-founder, president, and CEO, will present at the H.C. Wainwright BioConnect Virtual Conference occurring January 10-13, 2022. The presentation will be available for on-demand viewing starting Monday, January 10, 2022 at 7:00 a.m. ET.
An on-demand webcast of the presentation will be accessible under “News & Events” in the Investors section of the company’s website at www.sabbiotherapeutics.com.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB’s versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies. For more information on SAB, visit: http://www.sabbiotherapeutics.com and follow @SABBantibody on Twitter.
Contact:
Melissa Ullerich
+1 605-695-8350
mullerich@sabbiotherapeutics.com
FAQ
When is the H.C. Wainwright BioConnect Virtual Conference for SAB Biotherapeutics?
How can I watch the SAB Biotherapeutics presentation at the conference?
What is the focus of SAB Biotherapeutics?
What is the stock symbol for SAB Biotherapeutics?
What technology does SAB Biotherapeutics use for antibody production?
